Sunday 18 October 2026
Export ABVC’s income statement to Excel — free account
ABVC BioPharma, Inc.
ABVC Healthcare Biotechnology
ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023. In the quarter to June 2026, revenue grew 66,233.3%, EPS grew 76.9% and free cash flow grew 72.7%, each against the same quarter a year earlier.
0.92
0.01
−1.08%
Follow ABVC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | — |
P/S ratio |
54.20 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(73.29) | — | — | — | |
P/B ratio |
4.88 | — | — | — | |
Price to Tangible BV |
4.90 | — | — | — | |
EV/Sales |
54.83 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(23.06) | — | — | — | |
EV/FCF |
(22.87) | — | — | — | |
Quick Ratio |
0.14 | 0.35 | 0.07 | 0.02 | |
Current Ratio |
0.51 | 0.41 | 0.12 | 0.07 | |
Net Debt/EBITDA |
0.49 | 0.70 | 0.14 | 0.14 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.47 | 0.21 | 0.57 | 0.33 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(63.37) | (67.45) | (31.83) | (18.43) | |
Research and Development Expense of Revenue |
3.76% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
243.03% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
142.74% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.05) | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(7.88%) | — | — | — | |
Free Cash Flow Yield |
(4.42%) | — | — | — | |
Revenue per Share |
0.03 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.04) | (0.03) | (0.04) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.03) | (0.04) | (0.01) | |
Cash per Share |
0.04 | 0.07 | 0.01 | 0.00 | |
Shareholders Equity per Share |
0.62 | 0.66 | 0.50 | 0.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.62 | 0.66 | 0.50 | 0.47 | |
Free Cash Flow |
(0.96) | (0.59) | (0.89) | (0.24) | |
Working Capital |
(3.23) | (3.66) | (4.74) | (5.28) | |
Net Current Asset Value |
(3.41) | (5.26) | (6.26) | (6.72) | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.00 | — | — | — | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
— | 0.39 | 0.10 | — | |
Average Inventory |
0.02 | — | — | — | |
Average Assets |
17.84 | 14.30 | 17.30 | 17.82 | |
Average Common Equity |
11.24 | 7.01 | 10.39 | 10.88 |
Columns are period end dates · fundamentals updated 28 Sep 2026